
“We are approaching an important inflection point in the evolution of CNS Pharmaceuticals (CNSP),” said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. “Our efforts to identify and
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CNSP | CNS Pharmaceuticals | 3.48 | -4.83 | -58.12% |
| Name | Price | % Change | |
|---|---|---|---|
| $3.48 | -58.12% |

“We are approaching an important inflection point in the evolution of CNS Pharmaceuticals (CNSP),” said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. “Our efforts to identify and

Cash and cash equivalents were approximately $17.2 million as of September 30, 2026, compared to approximately $7.2 million as of December 31, 2025. The increase primarily reflects net proceeds from

The latest update is out from CNS Pharmaceuticals ( ($CNSP) ). On September 30, 2026, CNS Pharmaceuticals held its Annual Meeting of Stockholders, with 45.72% of the 1,461,449 outstanding common

CNS Pharmaceuticals (CNSP) participated in a Virtual Investor “What This Means” Segment in which Chief Business Officer Dylan Wenke provided an update on its business development strategy as part of

“We are moving with speed and discipline to transform this company,” said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals (CNSP). “In the second quarter, we significantly strengthened

The company said, “Since announcing its strategic pivot in March 2026 beyond a singular focus on glioblastoma multiforme, the Company has been leveraging its executive team’s multi-functional experience across high-value

Cash and cash equivalents were approximately $20.0 million as of June 30, 2026, compared to $7.2 million as of December 31, 2025. The increase primarily reflects the Company’s previously announced

CNS Pharmaceuticals ( ($CNSP) ) has provided an announcement. On July 2, 2026, CNS Pharmaceuticals posted a June 2026 investor presentation outlining a disciplined strategic reset anchored in oncology and

16:57 EDT CNS Pharmaceuticals (CNSP) files to sell 9.79M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

“We believe CNS Pharmaceuticals (CNSP) has entered a transformational new phase defined by strategic clarity, financial strength and disciplined execution,” said Rami Levin, President and Chief Executive Officer of CNS
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | May 15, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Nov 18, 2026TBA | $4.22M | $-0.27 | ― | 0.00 | -0.12 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.